- Home
- VMD vs NYXH Comparison
VMD vs NYXH Comparison
Compare VMD & NYXH Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- VMD
- NYXH
- Stock Information
- Founded
- VMD 2006
- NYXH 2009
- Country
- VMD United States
- NYXH Belgium
- Employees
- VMD N/A
- NYXH N/A
- Industry
- VMD
- NYXH Medical/Dental Instruments
- Sector
- VMD
- NYXH Health Care
- Exchange
- VMD Nasdaq
- NYXH Nasdaq
- Market Cap
- VMD 273.5M
- NYXH 273.3M
- IPO Year
- VMD N/A
- NYXH 2021
- Fundamental
- Price
- VMD $7.10
- NYXH $7.42
- Analyst Decision
- VMD
- NYXH Strong Buy
- Analyst Count
- VMD 0
- NYXH 4
- Target Price
- VMD N/A
- NYXH $14.50
- AVG Volume (30 Days)
- VMD 317.1K
- NYXH 58.2K
- Earning Date
- VMD 08-06-2025
- NYXH 08-18-2025
- Dividend Yield
- VMD N/A
- NYXH N/A
- EPS Growth
- VMD 47.14
- NYXH N/A
- EPS
- VMD 0.34
- NYXH N/A
- Revenue
- VMD $240,884,000.00
- NYXH $4,716,818.00
- Revenue This Year
- VMD $17.35
- NYXH $209.22
- Revenue Next Year
- VMD $12.87
- NYXH $219.37
- P/E Ratio
- VMD $20.97
- NYXH N/A
- Revenue Growth
- VMD 17.11
- NYXH N/A
- 52 Week Low
- VMD $5.93
- NYXH $5.55
- 52 Week High
- VMD $9.81
- NYXH $11.87
- Technical
- Relative Strength Index (RSI)
- VMD 65.58
- NYXH 46.85
- Support Level
- VMD $5.93
- NYXH $7.22
- Resistance Level
- VMD $6.41
- NYXH $7.65
- Average True Range (ATR)
- VMD 0.20
- NYXH 0.35
- MACD
- VMD 0.09
- NYXH -0.03
- Stochastic Oscillator
- VMD 95.51
- NYXH 52.53
About VMD Viemed Healthcare Inc.
Viemed Healthcare Inc is a provider of medical equipment and home therapy to patients with respiratory disease, oxygen problems, sleep apnea and PAP treatment. The company also provides services such as respiratory disease management, neuromuscular care, in-home sleep testing and sleep apnea treatment, oxygen therapy, respiratory equipment rentals, and healthcare staffing services. The company generates majority its revenue from medical equipment rental, sales and supply.
About NYXH Nyxoah SA
Nyxoah SA is a health-technology company focused on the development and commercialization of solutions and services to treat sleep-disordered breathing conditions. The company's solution platform is based on the Genio system, a CE-Mark validated, user-centered, bilateral neurostimulation therapy to treat moderate to severe Obstructive Sleep Apnea (OSA), the common sleep disordered breathing condition that is associated with increased mortality risk and comorbidities including cardiovascular diseases, depression and stroke.